Skip to main content

neo212

Generic: Temozolomide Perillyl Alcohol Conjugate NEO212·Code: NEO212

neo212: developed by 1 company · 1 clinical trial tracked.

neo212 evidence translation

What we can confirm

What it means

Source-backed records connect neo212 to NTHI; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could neo212 → NTHI affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Diffuse Astrocytoma, IDH-Mutant
Phase 1/Phase 2
Clinical Trials (1)

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.

NCT06047379·Phase 1/Phase 2·NTHI
Recruiting

Primary endpoint: Phase 1: safety and tolerability of increasing dose levels of orally administered NEO212 alone in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or patients with select solid tumors with uncontrolled metastases to the brain

Interventionalopen134 targetStarted 2023-11Completion 2027-087 sites · United StatesNeonc Technologies, Inc.

Frequently asked questions

Who is developing neo212?

neo212 is being developed by NEONC TECHNOLOGIES HOLDINGS, INC..

How many clinical trials involve neo212?

BioSniper tracks 1 clinical trial involving neo212.